A Study of Vaniprevir (MK-7009) in Patients With Chronic Hepatitis C Infection After Participation in Other Vaniprevir Studies (MK-7009-028 AM5)
| Status: | Completed |
|---|---|
| Conditions: | Hepatitis |
| Therapuetic Areas: | Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 11/18/2012 |
| Start Date: | June 2010 |
| End Date: | June 2014 |
| Contact: | Toll Free Number |
| Phone: | 1-888-577-8839 |
A Phase II Open Label Study of MK-7009 Administered Concomitantly With Pegylated Interferon Alfa-2a and Ribavirin to Patients With Chronic Hepatitis C Infection After Participation in Other MK-7009 Clinical Trials
This study will provide vaniprevir 600 mg or 300 mg twice daily in combination with
pegylated interferon and ribavirin to participants with chronic hepatitis C virus (HCV)
infection who did not achieve viral eradication while participating in a prior vaniprevir
clinical trial.
Inclusion criteria:
- Participant has participated in a prior vaniprevir clinical trial
- Participant agrees to use acceptable birth control method during treatment
Exclusion criteria:
- More than one year has passed since the participant was determined to be eligible for
enrollment in protocol 028
- Participant discontinued vaniprevir and/or peg-IFN and/or RBV in the prior study due
to a safety or tolerability issue
- Participant received any investigational therapy for HCV after participating in the
prior study
We found this trial at
1
site
Click here to add this to my saved trials
